Pure Global
NCT06421311

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

Ambispective Observational Study of Muscle Invasive Urothelial Carcinoma Patients Treated With Adjuvant Nivolumab in France
Bristol-Myers Squibb·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
nivolumab
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Bristol-Myers Squibb
Location
Strasbourg, France
Timeline & enrollment
Phase
N/A
Start date
Jun 15, 2024
End date
May 01, 2028
Enrollment
300 participants
Primary outcome

Disease-free survival (DFS) of participants

Summary

This study will estimate the real-world effectiveness of adjuvant nivolumab therapy in adult
 participants with muscle invasive urothelial carcinoma (MIUC) in France.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06421311
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06421311 through Pure Global AI's free database. This phase not specified trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.